ABVX
Abivax S.A.
$144.65
+12.09 (+9.12%)
At close · Jul 2
Market Cap
$11.54B
Shares
78,536,412
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$144.65
Open$138.87
Day$137.63–146.68
52W$7.65–148.83
Avg vol 30d2.9M
Short int4.9M · 6.2% float · 1.2d
Short vol20%
Last earningsDec 31, 2023
DataOct 2023–Jul 2026
Equibles Rating
blended score · not investment advice
Overall
Strong Buy
Technical · trend & momentum
Strong Buy
+
50 / 200-day cross
golden cross
+
Price vs 200-day avg
+29% above
+
Price vs 50-day avg
+29% above
◦
RSI (14)
70 · neutral
+
MACD trend
positive
+
52-week position
97% · near high
Sentiment · smart money
Bullish
+
Trend (MA cross)
50d $112 › 200d $112 — 50d above 200d
+
Institutional flow
1 of 254 funds reported for Jun 30 · net +226 sh shares · +1 new
◦
Insider flow
No net insider activity over 90 days
−
Short interest
6.22% of float · ▲ +60.0% MoM · 1.2 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
254 holders — near 2-yr high, broad support
Fundamentals
Limited data
Not enough data for a confident read.
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
golden cross
Bullish
Price vs 200-day avg
+29% above
Bullish
Price vs 50-day avg
+29% above
Bullish
RSI (14)
70 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
97% · near high
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
Golden cross
50d $112 › 200d $112 — 50d above 200d
Institutional flow
Accumulating
1 of 254 funds reported for Jun 30 · net +226 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.22% of float · ▲ +60.0% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
254 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $8
Now $145 · 97%
52-wk high $149
vs 200-day avg +29%
vs 50-day avg +29%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABVX
this stock
Abivax S.A.
|
$11.54B | +7.3% | — | — | 6.2% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABVX | +56.6% | +60.5% | +25.3% | +8.6% | +7.3% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +55.2% | +61.7% | +17.2% | +8.8% | -2.0% |